Entering text into the input field will update the search result below

IDEAYA announces dose expansion of Phase 1/2 study on metastatic uveal melanoma

Mar. 23, 2021 8:46 AM ETIDEAYA Biosciences, Inc. (IDYA) Stock, PFE StockPFE, IDYABy: Dulan Lokuwithana, SA News Editor
  • IDEAYA Biosciences (NASDAQ:IDYA) announced dose expansion of the ongoing Phase 1/2 study evaluating the combination of IDE196 and binimetinib in metastatic uveal melanoma ("MUM").
  • The company expects to enroll ~40 patients for the IDE196 and binimetinib combination arm in the trial conducted in

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
PFE
--
IDYA
--